Tyrosine kinase inhibitor sorafenib decreases 111in-girentuximab uptake in patients with clear cell renal cell carcinoma

Journal of Nuclear Medicine

Volumn 55, Issue 2, 2014, Pages 242-247

  Muselaers, Constantijn H J ^a   Stillebroer, Alexander B ^a   Desar, Ingrid M E ^a   Boers Sonderen, Marye J ^a   Van Herpen, Carla M L ^a   De Weijert, Mirjam C A ^a   Langenhuijsen, Johan F ^a   Oosterwijk, Egbert ^a   Leenders, William P J ^a   Boerman, Otto C ^a   Mulders, Peter F A ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CAIX; Girentuximab; Imaging; Renal cell carcinoma; Tyrosine kinase inhibitor

Indexed keywords

CARBONATE DEHYDRATASE IX; CD31 ANTIGEN; INDIUM GIRENTUXIMAB IN 111; RADIOPHARMACEUTICAL AGENT; SORAFENIB; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; G250 MONOCLONAL ANTIBODY; GIRENTUXIMAB; INDIUM; MONOCLONAL ANTIBODY; NICOTINAMIDE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; KIDNEY CARCINOMA; MALE; MIDDLE AGED; NEPHRECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCINTIGRAPHY; SKIN TOXICITY; STOMATITIS; ADJUVANT THERAPY; CAIX; CLINICAL TRIAL; DRUG POTENTIATION; IMAGING; INTERVENTION STUDY; KIDNEY TUMOR; METABOLISM; METHODOLOGY; SCINTISCANNING;

CAIX; GIRENTUXIMAB; IMAGING; RENAL CELL CARCINOMA; TYROSINE KINASE INHIBITOR;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; CARCINOMA, RENAL CELL; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIUM RADIOISOTOPES; INTERVENTION STUDIES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN-TYROSINE KINASES; RADIONUCLIDE IMAGING;

EID: 84897946508     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.131110     Document Type: Article

References (28)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356: 115-124.
2. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med. 2007;356: 125-134.
3. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28: 1061-1068.
4. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors: a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10: 470-481.
5. Desar IM, Mulder SF, Stillebroer AB, et al. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients -A report of three cases. Acta Oncol. 2009;48: 927-931.
6. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38: 489-494.
7. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9: 802-811.
8. Leibovich BC, Sheinin Y, Lohse CM, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol. 2007;25: 4757-4764.
9. Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res. 1998;4: 2729-2739.
10. 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res. 1999;5(suppl)3268s-3274s.
11. 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med. 2004;45: 1412-1421.
12. 131I] cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res. 2005;11(suppl): 7178s-7186s.
13. 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol. 2005;23: 6540-6548.
14. 177Lu, or 186Re. J Nucl Med. 2004;45: 327-337.
15. Stillebroer AB, Boerman OC, Desar IM, et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2013;64: 478-485.
16. A randomized, double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence (ARISER). ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ ct2/show/NCT00087022. Published July 8, 2004. Updated May 21, 2013. Accessed December 11, 2013.
17. 111In: an intrapatient comparison. Clin Cancer Res. 2003;9(suppl): 3953S-3960S.
18. Visser E, Postema E, Boerman O, Visschers J, Oyen W, Corstens F. Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND). Eur J Nucl Med Mol Imaging. 2007;34: 413-421.
19. Muselaers CH, Boerman OC, Oosterwijk E, Langenhuijsen JF, Oyen WJ, Mulders PF. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol. 2013;63: 1101-1106.
20. 111In- bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. J NuclMed. 2010;51: 1707-1715.
21. Nagengast WB, Lub-de Hooge MN, Oosting SF, et al. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res. 2011;71: 143-153.
22. Oosterwijk-Wakka JC, Kats-Ugurlu G, Leenders WP, et al. Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250. BJU Int. 2011;107: 118-125.
23. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307: 58-62.
24. Ross H, Martignoni G, Argani P. Renal cell carcinoma with clear cell and papillary features. Arch Pathol Lab Med. 2012;136: 391-399.
25. Russell J, Carlin S, Burke SA,Wen B, Yang KM, Ling CC. Immunohistochemical detection of changes in tumor hypoxia. Int J Radiat Oncol Biol Phys. 2009;73: 1177-1186.
26. 124I-cG250 for the early detection of response to sunitinib in patients with metastatic renal cell carcinoma. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01582204. Published April 18, 2012. Updated June 25, 2013. Accessed December 11, 2013.
27. Francescone R, Scully S, Bentley B, et al. Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem. 2012;287: 24821-24831.
28. Scully S, Francescone R, Faibish M, et al. Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas. J Neurosci. 2012;32: 12950-12960.